$2.59
1.57% yesterday
Nasdaq, May 22, 10:00 pm CET
ISIN
CA88338H1001
Symbol
THTX
Sector
Industry

Theratechnologies Inc. Stock price

$2.59
-0.14 5.13% 1M
+1.39 115.83% 6M
+0.78 43.09% YTD
+1.32 103.94% 1Y
-7.37 74.00% 3Y
-5.69 68.72% 5Y
-1.85 41.66% 10Y
Nasdaq, Closing price Thu, May 22 2025
+0.04 1.57%
ISIN
CA88338H1001
Symbol
THTX
Sector
Industry

Key metrics

Market capitalization $117.45m
Enterprise Value $163.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.84
P/S ratio (TTM) P/S ratio 1.32
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 13.53%
Revenue (TTM) Revenue $88.67m
EBIT (operating result TTM) EBIT $12.32m
Free Cash Flow (TTM) Free Cash Flow $-17.26m
Cash position $4.34m
EPS (TTM) EPS $-0.08
P/E forward 27.26
P/S forward 1.44
EV/Sales forward 2.00
Short interest 1.33%
Show more

Is Theratechnologies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,788 stocks worldwide.

Theratechnologies Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Theratechnologies Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Theratechnologies Inc. forecast:

Buy
100%

Financial data from Theratechnologies Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Feb '25
+/-
%
89 89
14% 14%
100%
- Direct Costs 19 19
8% 8%
21%
70 70
21% 21%
79%
- Selling and Administrative Expenses 42 42
2% 2%
47%
- Research and Development Expense 16 16
35% 35%
18%
15 15
429% 429%
17%
- Depreciation and Amortization 2.74 2.74
5% 5%
3%
EBIT (Operating Income) EBIT 12 12
265% 265%
14%
Net Profit -3.71 -3.71
79% 79%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Theratechnologies Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theratechnologies Inc. Stock News

Neutral
GlobeNewsWire
21 days ago
VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual A...
Negative
Seeking Alpha
about one month ago
Theratechnologies is likely to accept Future Pak's $255 million offer, presenting a 39%-78% premium over current share prices, despite non-binding risks. The company's HIV franchise, led by EGRIFTA SV, faces competition and supply issues, with uncertain prospects for its new formulation and other niche products. Theratechnologies' financials are dire, with only $4.6 million in cash and a high b...
Neutral
GlobeNewsWire
about one month ago
MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further e...
More Theratechnologies Inc. News

Company Profile

Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.

Head office Canada
CEO Paul Lévesque
Employees 103
Founded 1993
Website www.theratech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today